Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a herbal mist soothe dry eyes? new study investigates

NCT ID NCT06089317

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a fine mist made from traditional Chinese herbs can help people with dry eye disease. 200 adults received either the herbal mist, a placebo mist, or standard eye drops for 4 months. Researchers measured symptom scores and tear film stability to see if the TCM mist offers extra relief beyond artificial tears.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

200 people

The number who actually took part.

Started

Jul 2024

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: 1. At least one eye of subjects meets DED diagnostic criteria as the Tear Film and Ocular Surface Society (TFOS) Dry Eye Workshop (DEWS II); and 2. Ocular Surface Disease Index (OSDI)≥13 and \<33; and 3. The age range between years 18-80, no sex limitation; and 4. Symptoms of dry eye for at least 6 months; and 5. Can complete the questionnaires independently and understand Chinese or English. Exclusion criteria: 1. Had or currently suffering from other concomitant ocular surface diseases, including chronic conjunctivitis, ocular rosacea, cicatricial pemphigoid, graft-versus-host disease, limbal stem cell deficiency, and severe ocular allergy; 2. Received any refractive surgery and corneal surgery before, including corneal transplant; or any eye surgery in the past 6 months; 3. Receiving DED-related medications, including topical steroid eyedrops, topical antibiotics, topical cyclosporin A, and topical diquafosol; 4. Received intense pulsed laser (IPL) or vectored thermal pulsation (VTP) therapy in the past 12 months; 5. Received topical antiglaucomatous treatment in the past 12 months 6. Plans to use contact lenses during treatment and follow-up periods or used contact lenses 2 weeks before the baseline measurement and recruitment; 7. Had or currently suffering from severe cardiopulmonary disease, liver and kidney dysfunction, and severe blood system diseases; 8. Suffering from glucose-6-phosphate dehydrogenase deficiency (G6PD); 9. Had or currently suffering from specific respiratory diseases, e.g. emphysema, bronchitis, asthma, chronic obstructive pulmonary disease, bronchial dilatation; 10. Has adverse reaction history to herbs used in this study before; 11. Whose TCM constitution is manifested as "yang-deficiency" or diagnosed by TCM practitioners that their TCM syndrome is not suitable for the atomization treatment; 12. Pregnancy, preparation for pregnancy, or lactation;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dry eye syndromes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hong Kong Eye Hospital

    Kowloon, Hong Kong, Hong Kong

  • Prince of Wales Hospital

    Shatin, 000000, Hong Kong

  • The CUHK Medical Centre (CUHKMC)

    Shatin, 000 000, Hong Kong

  • The Chinese University of Hong Kong Eye Centre (CUHKEC)

    Kowloon, 000000, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.